U.S. Capital Wealth Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.12M	Sell	24,537 -2,806	-10%	-$955K	0.2%	117
2025 Q4	$10.9M	Sell	27,343 -201	-0.7%	-$89K	0.28%	82
2025 Q3	$12.6M	Sell	27,544 -24,483	-47%	-$9.97M	0.34%	67
2025 Q2	$17M	Sell	52,027 -3,984	-7%	-$1.1M	0.5%	43
2025 Q1	$15.1M	Sell	56,011 -4,490	-7%	-$1.15M	0.46%	49
2024 Q4	$14.2M	Sell	60,501 -999	-2%	-$263K	0.44%	50
2024 Q3	$16.9M	Hold	61,500	–	–	0.6%	30
2024 Q2	$14.9M	Hold	61,500	–	–	0.57%	36
2024 Q1	$9.19M	Hold	61,500	–	–	0.35%	62
2023 Q4	$11.8M	Hold	61,500	–	–	0.47%	45
2023 Q3	$10.9M	Buy	+61,500	New	+$11.7M	0.49%	41

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

U.S. Capital Wealth Advisors's ALNY Position: Q1 2026 in Review

U.S. Capital Wealth Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 10% in Q1 2026, selling an estimated $955K and leaving 24,537 shares worth $8.12M. The position accounts for 0.2% of the portfolio, ranked #117.

U.S. Capital Wealth Advisors first reported a position in ALNY in Q3 2023 and has held it in 11 quarters since. The position peaked at $17M in Q2 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

U.S. Capital Wealth Advisors held 24,537 shares of Alnylam Pharmaceuticals worth $8.12M as of Q1 2026.
U.S. Capital Wealth Advisors sold 2,806 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $955K.
Alnylam Pharmaceuticals made up 0.2% of U.S. Capital Wealth Advisors's portfolio in Q1 2026, its #117 holding.
U.S. Capital Wealth Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
U.S. Capital Wealth Advisors's Alnylam Pharmaceuticals position peaked at $17M in Q2 2025.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2026, filed 7 Apr 2026.